Figure 3. The proinflammatory cytokine levels of TNF-α, IL-17, and IL-6 in the serum samples from the treated and control group. (means±SD; n=7 per group; *P<0.05, ** P<0.01, *** P<0.001).

Conclusion: Leflunomide may prevent and improve salivary gland hypofunction and inhibit immune activation in NOD mice, providing a theoretical basis for evaluating leflunomide in the treatment of Sjögren’s syndrome.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4229

THU0230

HSA-MIR-513C-3P OVEREXPRESSION DECREASES XBP-1S CORRELATING WITH INCREASED INFLAMMATION AND AUTOANTIBODIES IN SALIVARY GLANDS FROM SJÖGREN’S SYNDROME PATIENTS

P. Carvalho1, S. Aguillera2, B. Heathcoate1, I. Castro3, D. Jara4, M. J. Barrera5, V. Maracaia1, S. Gonzalez2, V. Alaga1, C. Molina1, M. J. Gonzalez1.

1Universidad de Chile, Programa de Biología Celular y Molecular; 2Instituto de Ciencias Biomédicas, Facultad de Medicina, Santiago, Chile; 3Clínica Indisa, Reumatología, Santiago, Chile; 4Universidad de Chile, Departamento de Tecnología Médica, Facultad de Medicina, Santiago, Chile; 5Universidad San Sebastián, Facultad de Odontología, Santiago, Chile; 6Universidad de Chile, Departamento de Bioquímica y Biología Molecular; Facultad de Ciencias Químicas y Farmacéuticas, Santiago, Chile; 7Universidad Mayor, Escuela de Odontología, Facultad de Ciencias, Santiago, Chile

Background: Endoplasmic reticulum (ER) stress and the Unfolded Protein Response (UPR) are linked to inflammation in a variety of human pathologies including autoimmune diseases. Salivary glands (SG) from Sjögren’s syndrome (SS) patients have high levels of IFN-α/γ among other cytokines, which trigger or exacerbate protein unfolding or misfolding, inducing ER stress. In this study, we focused on the IRE1α/XBP-1 pathway of the UPR, whose transcription factor is XBP-1s, which induces genes linked to regulation of the secretory pathway. We recently found that SG of SS patients have reduced levels of XBP-1s transcripts associated with an increased DNA methylation of XBP-1 promoter [1]. We postulate that other epigenetic mechanisms, such as miRNAs, could coexist with promoter DNA hyper-methylation to regulate XBP-1s expression.

Objectives: Due to hsa-miR-513c-3p overexpression has been reported in SG from SS patients [2] and that XBP-1 is a predicted target of hsa-miR-513c-3p, the aim of this study was to evaluate whether mRNA levels of XBP-1s is modulated by hsa-miR-513c-3p and also if IFN-γ/αnema modification can provoke the expression hsa-miR-513c-3p and XBP-1s.

Methods: SG biopsies from 16 SS-patients with low and high focus score and 5 controls were analyzed. hsa-miR-513c-3p levels were measured by Taqman assays, whereas XBP-1s mRNA levels were determined by qRT-PCR. Additionally, in vitro assays using IFN-γ/αnema and chemically synthesized hsa-miR-513c-3p mimics and inhibitors were performed to study its effect on XBP-1s expression.

Results: By Taqman assays we validated the overexpression of hsa-miR-513c-3p in SG from 8 SS patients with low (p=0.03) and 8 SS-patients with high (p=0.003) focus score, compared with SG from 5 controls. In the same samples, a decrease of XBP-1s transcript levels was observed in SS-patients with low (p=0.002) and high (p=0.026) focus score. XBP-1s transcript levels were negatively correlated with hsa-miR-513c-3p (r=-0.47, p=0.014), Ro (r=-0.73, p=0.0009), ANA (r=-0.7, p=0.0033) and focus score (r=-0.72, p=0.001). Stimulation of 3D-acinia with 1ng/mL IFN-γ/αnema increase the hsa-miR-513c-3p levels (p=0.014) and decrease the XBP-1s transcript levels (p=0.027). A negative correlation was found between hsa-miR-513c-3p and XBP-1s transcript levels in 3D-acinia stimulated with IFN-γ/αnema (r=-0.87, p=0.0001). The XBP-1s transcript levels were decreased in HSG cells transfected with hsa-miR-513c-3p mimic and increased in HSG cells transfected with the miRNA inhibitor.

Conclusion: IFN-γ/αnema-induced upregulation of hsa-miR-513c-3p is consistent with the presence of STAT1-binding elements in its promoter region. Our findings suggest that the combined action of miRNAs and DNA methylation modulated by IFN-γ/αnema could explain the altered expression of XBP-1s, a key transcription factor involved in cellular proteostasis, affecting secretory function in LSG from SS-patients. Our results confirm previous correlations found between XBP-1s protein levels and clinical parameters of SS-patients, suggesting an association of XBP-1s with inflammation and impaired SG function.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2215

THU0231

IGG1 ANTIBODIES AGAINST PHOSPHORYLCHOLINE ARE NEGATIVELY ASSOCIATED WITH DISEASE ACTIVITY, DISEASE DAMAGE, CARDIOVASCULAR DISEASE AND ATHEROSCLEROSIS IN SLE: POTENTIAL UNDERLYING MECHANISMS.

D. Thiggarajan1, R. Fiskesund2, J. Steen1, M. Rahman1, S. Lundström1, J. Frostegård1.

1Karolinska Institutet, Stockholm, Sweden

Background: Phosphorylcholine (PC) is an important component in cellular membranes and in lipoproteins that is exposed and recognized by the immune system, when cells undergo apoptosis or lipoproteins like LDL undergo oxidation. PC is also exposed in some microorganisms including nematodes and bacteria (non-self). We reported that IgM anti-PC is associated with protection in atherosclerosis, SLE, RA and other chronic inflammatory conditions.1 We also reported potential underlying protective mechanisms: 1: increase in clearance of human dead cells,2: inhibition of uptake of oxLDL in macrophages, 3: inhibition of cell death.1 4: anti-inflammatory; 5: promotion of polarization of T regulatory cells in SLE-patients’ T cells from a low level and also in plaque T cells.3 We generated in-house fully human IgG1 anti-PC clones for experimental studies to study anti-PC properties in humans. In contrast to mice, anti-PC are not germ-line encoded with a dominant clone.4

Objectives: We here study IgG1 and IgG2 anti-PC, with focus on atherosclerosis and SLE and properties of fully human IgG1 clones, in relation to SLE.

Methods: We determined anti-PC by ELISA in 116 SLE-patients and 110 age- and sex-matched controls. For functional studies, we used three in-house generated, fully human monoclonal IgG1 anti-PC (A01, D05, E01). Apoptosis was induced in Jurkat T-cells and pre-incubated with A01, D05, E01 or isotype control IgG1 and effects on efferocytosis by human macrophages studied. Anti-PC peptide/protein characterization was determined using a proteomics de novo sequencing approach.

Results: IgG1 but not IgG2 anti-PC levels were higher among SLE patients (p=0.02). IgG1 anti-PC was negatively associated with SLICC and SLEDAI (OR: 2.978 CI: 0.876-10.98, OR: 5.108 CI 1.3 20.067 respectively) and negatively associated with CVD, atherosclerotic plaques and eeholocent (potentially vulnerable plaques) but the association for the two former was not significant after controlling for confounders. D05 had maximum effect on macrophage efferocytosis efficiency, followed by A01 and E01. The monoclonal antibodies showed differential binding specificity to PC and PC associated neo-epitopes. Peptide analysis showed difference in the CDR3 region of the three anti-PC IgG1 clones which are crucial for recognition of PC on apoptotic cell surface and other neo-epitopes.

Conclusion: Anti-PC IgG1 is negatively associated with disease activity, and disease damage in SLE, but the negative association with CVD is also dependent on confounding risk factors. One potential underlying mechanism could be increased clearance of dead cells.

References: